Spero Therapeutics, Inc. business relationships
Companies named in Spero Therapeutics, Inc.’s 10-K filed 2026-03-26, and public companies whose annual reports name Spero Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 12 / 100 Top 2% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in Spero Therapeutics, Inc.’s annual report 10
“The Company determined that the supply agreement is a customer option and not a material right, as the pricing to Pfizer is not at a significant discount.” SEC filing
“The Pfizer Territory excludes the United States and the Asian markets previously licensed to Everest in the Everest Territory.” SEC filing
“Changes in deferred revenue are related to the GSK License Agreement and our license agreement with Pfizer.” SEC filing
“During the year ended December 31, 2024 we recognized $0.4 million in collaboration revenue related to our agreement with Pfizer.” SEC filing
“Pursuant to the terms of the GSK License Agreement, we granted GSK an exclusive royalty-bearing license, with the right to grant sublicenses, under our intellectual property and regulatory documents and a sublicense under certain intellectual property of Meiji and Meiji's regulatory documents to dev...” SEC filing
“Amendments to the GSK License Agreement” SEC filing
“As a result, we are currently substantially dependent on our tebipenem program and our collaboration with GSK.” SEC filing
“The Pfizer Territory excludes the United States and the Asian markets previously licensed to Everest in the Everest Territory.” SEC filing
“We have recognized revenue to date from funding arrangements with the DoD, NIAID, CARB-X and BARDA, the GSK License Agreement and our license agreements with Everest and Pfizer.” SEC filing
“In May 2016, the Company entered into an agreement with Vertex Pharmaceuticals Incorporated ("Vertex") (the "Vertex Assignment and License Agreement") whereby Vertex granted the Company certain know-how and a sublicense to research, develop, manufacture and sell products for a proprietary compound,...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.